• SIS3: A Next-Generation Smad3 Inhibitor Empowering Fibros...

  2025-10-01

  Discover how the selective Smad3 inhibitor SIS3 advances TGF-β pathway research, offering unique mechanistic insights and translational potential for fibrosis and osteoarthritis models. This article provides an in-depth exploration distinct from standard reviews.

• SIS3: Advanced Smad3 Inhibition for Fibrosis and Diabetic...

  2025-09-30

  Explore how SIS3, a selective Smad3 inhibitor, enables breakthrough research in fibrosis, renal disease, and diabetic nephropathy by precisely targeting TGF-β/Smad signaling. This article delivers a unique systems-biology perspective and translational insights beyond conventional reviews.

• SIS3: Transforming Fibrosis and Osteoarthritis Research v...

  2025-09-29

  Explore how SIS3, a selective Smad3 phosphorylation inhibitor, is redefining fibrosis and osteoarthritis research by enabling targeted modulation of the TGF-β/Smad signaling pathway. This article provides a novel systems-level analysis of SIS3’s applications, mechanisms, and translational potential, distinguishing itself from existing reviews.

• SIS3: Unveiling Smad3 Inhibition in Cartilage and Fibrosi...

  2025-09-28

  Discover how SIS3, a selective Smad3 inhibitor, advances the understanding of TGF-β/Smad signaling in cartilage homeostasis and fibrosis models. This article explores SIS3’s unique mechanisms, applications in osteoarthritis and renal disease, and provides a scientific perspective distinct from existing summaries.

• DMH1: Unlocking Selective BMP Inhibition for Organoid Inn...

  2025-09-27

  Discover how DMH1, a selective BMP type I receptor inhibitor, enables unprecedented precision in manipulating stem cell fate and suppressing lung tumor growth. This article offers unique mechanistic insights and strategic applications of DMH1 beyond current literature.

• DMH1 as a Precision BMP Signaling Modulator: Beyond Cance...

  2025-09-26

  Explore how DMH1, a selective BMP type I receptor inhibitor, uniquely enables precise modulation of stem cell fate and tumor suppression. Discover distinct applications in organoid engineering and lung cancer research, setting this article apart from existing overviews.

• Phosbind Acrylamide: Transforming Quantitative Phosphoryl...

  2025-09-25

  Discover how Phosbind Acrylamide, a breakthrough phosphate-binding reagent, enables precise and quantitative protein phosphorylation analysis without phospho-specific antibodies. Explore its pivotal role in dissecting processive phosphorylation and signaling pathway complexity.

• Influenza Hemagglutinin (HA) Peptide: Next-Generation Str...

  2025-09-24

  Explore the advanced use of Influenza Hemagglutinin (HA) Peptide in quantitative protein purification and mechanistic cancer research. Discover how this high-purity HA tag peptide enables precise detection, competitive elution, and innovative applications beyond standard protocols.

• Cy5-UTP in Axonal mRNA Trafficking: Advanced RNA Labeling...

  2025-09-23

  Explore how Cy5-UTP (Cyanine 5-uridine triphosphate), a fluorescently labeled UTP for RNA labeling, enables precise investigation of axonal mRNA trafficking and aggregation dynamics in neurodegenerative research. This article details protocols, mechanistic insights, and the relevance of in vitro transcription RNA labeling for neuronal studies.

• It is interesting that Li et

  2025-03-03

  

  It is interesting that Li et al. (2008) reported that AChR-immunized FcγRIIB knock out (KO) mice are significantly resistant to antibody-mediated EAMG. This is in contrast with previous studies, but does not contradict the results presented here. Despite their observation that the incidence and seve

• The cytoplasmic domain of muscle AChR is not

  2025-03-03

  

  The cytoplasmic domain of muscle AChR is not accessible to Dyngo-4a in vivo. Theoretically, therapy with the cytoplasmic domains should be safe. Safety is demonstrated by the facts that: (1) rats repeatedly immunized with the cytoplasmic domains in TiterMax adjuvant do not develop EAMG, although th

• CID 2745687 receptor Tacrine an aminoacridine derivative Fig

  2025-03-03

  

  Tacrine, an aminoacridine derivative (Fig. 1, A), was the first AChE inhibitor approved for treatment of AD [12], [13]. This compound was withdrawn from the market due to its hepatotoxicity [14]. In spite of tacrine's side effects, it is still an attractive lead compound for medicinal chemists due t

• br Results br Discussion Dopamine regulates

  2025-03-03

  

  Results Discussion Dopamine regulates behavioral responses to nicotine in Drosophila (Bainton et al., 2000), but neurochemical measurements of dopamine after nicotine stimulation had not been made. Here, we demonstrate for the first time that the stimulation of nAChRs causes dopamine release i

• Molecular simulation has proven useful in describing the

  2025-03-01

  

  Molecular simulation has proven useful in describing the dynamics and energetics of NMDA receptor LBD cleft closure and the potentiating role of glycans (Yao et al., 2013, Dai and Zhou, 2013, Dai and Zhou, 2015, Dai and Zhou, 2016, Dutta et al., 2015, Omotuyi and Ueda, 2015, Sinitskiy and Pande, 20

• melanin However most of these SBVS studies were focused on

  2025-03-01

  

  However, most of these SBVS studies were focused on the target(s) for which crystal structures were available or have a similar template in PDB for comparative modeling. Besides, these were limited to SBVS only which relies on the rigid binding pocket, therefore, it may result in high false positive

15825 records 2/1055 page Previous Next 12345 下5页 Last page